Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients.Clinical Trial Registration : Clinicaltrials.gov, NCT03979313, https://clinicaltrials.gov/ct2/show/NCT03979313. No increase in the incidence of medically attended RSV lower respiratory tract infection or evidence of antibody-dependent enhancement of disease was found among nirsevimab recipients during their second RSV season in the Phase 3 MELODY trial compared with placebo recipients.